Sandra Calvin, SVP, Chief Accounting Officer at Travere Therapeutics, Inc. (TVTX), sold 558 shares at $16.12 ($9K) on 2023-05-11, disclosed to the SEC on 2023-05-12.
Scheduled sale ($9k) by SVP, Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.59 | 436 | $7K | 78.6% |
| 2 | $16.12 | 122 | $2K | 21.4% |
| Total | $16.49 avg | 558 | $9K | 100% |
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |